APP and Alzheimer disease: Remarkably, PPAR‐α agonists induce a nonamyloidogenic pathway via activation of α‐secretase, which is also called ADAM10, leading to decreased AD neuropathology by shifting APP proteolysis towards nonamyloidogenic Aβ.